CTLA4 and neoplasm: In the absence of PD-L1, CTLA-4 immuno-expression in tumor cells and related adjuncts like s-CTLA-4 levels in serum may be studied so as to analyse whether they conform as biomarker for predicting responsiveness to ICPIs.